At the presentation of the financial report for the nine months and third quarter ended 30 September 2020 Pharming Group N.V. CEO Sijmen de Vries says:
“We are pleased to announce continued growth, demonstrating consistent progress, despite the impact of the COVID-19 pandemic. We remain focused on, and are delivering against, our strategy for long-term growth. This includes continued sales growth of Ruconest through increasing market share for the treatment of acute HAE attacks.”
Operational highlights
- On 10 August 2020, the Company announced the enrollment of the first patient in a randomised, controlled, investigator-initiated clinical trial in up to 150 patients for treatment with rC1INH of patients with confirmed COVID-19 infections hospitalised with related severe pneumonia at the University Hospital Basel in Basel, Switzerland. This trial continues to recruit and has since expanded to other centres in Switzerland and is in the last stages of preparation in centres in Mexico and Brazil.
- On 17 August 2020, the Company announced the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use programme of five patients with confirmed COVID-19 infections hospitalized with related severe pneumonia that were treated with rhC1INH at the University Hospital Basel, Switzerland. >> The publication is available on Pharming’s website.
COVID-19 update
- No impact on the upscaling or continued production of Ruconest
- No impact on the availability or distribution of Ruconest to HAE patients
- The recruitment of new patients in ongoing clinical trials has been temporarily halted; patients already incorporated into ongoing clinical trials are continuing to receive treatment
(Source: Pharming)
